Ganbold Battuya, Nguyen Ba Trung, Hung Jia-Horung, Mobasserian Azadeh, Thng Zheng Xian, Ghoraba Hashem, Yavari Negin, Feky Dalia El, Yasar Cigdem, Saengsirinavin Aim-On, Zhang Xiaoyan, Anover Frances Andrea, Mohammadi S Saeed, Tuong Ngoc, Than Trong, Khatri Anadi, Elaraby Osama, Akhavanrezayat Amir, Gupta Ankur Sudhir, Yoo Woong Sun, Nguyen Quan Dong, Or Christopher
Spencer Center for Vision Research, Byers Eye Institute at Stanford University, 2452 Watson Court, Suite 200, Palo Alto, CA, 94303, USA.
Bolor Melmii Eye Hospital, Ulaanbaatar, Mongolia.
J Ophthalmic Inflamm Infect. 2025 May 6;15(1):40. doi: 10.1186/s12348-025-00494-6.
To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex) injection (SDI).
A retrospective case series of 4 patients (6 eyes).
In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (n = 1), and granulomatosis with polyangiitis (GPA) (n = 1). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (n = 2). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.
SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.
报告一组对多种常规治疗方法耐药的非感染性前巩膜炎病例，最终通过结膜下注射地塞米松植入剂（Ozurdex）（SDI）成功治疗。
回顾性病例系列研究，共4例患者（6只眼）。
在该病例系列中，患者平均年龄57.2岁（范围36至82岁，标准差19.2岁），50%为女性。2例患者有潜在自身免疫性疾病：类风湿关节炎（n = 1）和肉芽肿性多血管炎（GPA）（n = 1）。另外2例患者在进行广泛的全身检查后被诊断为特发性前巩膜炎。SDI前的平均随访时间和平均伴随治疗次数分别为27（标准差17.7）个月和2（标准差0.81）次。所有患者在SDI后症状均得到缓解，疾病活动度显著改善，植入物吸收后仍持续较长时间。SDI后未发现巩膜溶解、感染或眼压升高。
SDI可能是耐药性非感染性前巩膜炎的一种安全有效的治疗选择。
